Toray Industries has developed technology to control the pore size of PMMA porous fibers in a range from a few nm to approximately 1,000nm. This enables the selective adsorption of pathogenic substances associated with intractable diseases such as autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer. The technology allows for high-efficiency removal of large molecular weight substances like autoantibodies, lipoproteins, and exosomes. Toray plans to advance the design and mass production for early clinical application.

FACT BOX

  • Source: PR Times
  • Category: product_launch